Treatment of advanced stage diffuse, small non‐cleaved cell lymphoma in childhood: Further experience with total therapy B

Timothy C. Griffin, W. Paul Bowman, Naomi J. Winick, George R. Buchanan

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Prior to the development of intensive treatments for patients with advanced stage B‐cell non‐Hodgkin's lymphoma (B‐NHL), the prognosis for such patients was dismal. A minority of patients attained long‐term, disease‐free survival. Since 1981, we have treated 28 children with advanced stage B‐NHL with an intensive chemotherapeutic protocol, Total Therapy B. This regimen employs cycles of fractionated high‐dose cyclophosphamide, doxorubicin, and vincristine alternating with sequential infusions of high‐dose methotrexate and escalating doses of cytarabine, in addition to intensive intrathecal therapy. The planned duration of therapy is approximately 6 months. Two patients had B‐cell acute lymphoblastic leukemia and 26 had stage III B‐NHL; none had CNS involvement. The median age was 7 years. All 28 patients achieved complete remission (CR). Both patients with B‐ALL and 21 of 26 with stage III B‐NHL remain in CR, with a median follow‐up of 51 months. Treatment failures included 3 patients with recurrent or progressive disease, 1 toxic death in CR, and 1 patient who developed a secondary mediastinal T‐cell lymphoblastic lymphoma 4 1/2 years after the diagnosis of B‐NHL. The 2‐ and 5‐year event‐free survival rates were 85.7 ± 6.6% (SE) and 79.6 ± 8.5%, respectively. Total Therapy B is a highly effective therapy for children with advanced stage B‐NHL without CNS involvement. © 1994 Wiley‐Liss, Inc.

Original languageEnglish
Pages (from-to)393-399
Number of pages7
JournalMedical and Pediatric Oncology
Volume23
Issue number5
DOIs
StatePublished - 1994

Fingerprint

Non-Hodgkin's Lymphoma
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Poisons
Cytarabine
Vincristine
Treatment Failure
Methotrexate
Doxorubicin
Cyclophosphamide
Survival Rate
Survival

Keywords

  • Burkitt's lymphoma
  • leukemia, B‐cell
  • lymphoma
  • small noncleaved‐cell

Cite this

@article{ae5f1cab3bf1489589d14032cb993b01,
title = "Treatment of advanced stage diffuse, small non‐cleaved cell lymphoma in childhood: Further experience with total therapy B",
abstract = "Prior to the development of intensive treatments for patients with advanced stage B‐cell non‐Hodgkin's lymphoma (B‐NHL), the prognosis for such patients was dismal. A minority of patients attained long‐term, disease‐free survival. Since 1981, we have treated 28 children with advanced stage B‐NHL with an intensive chemotherapeutic protocol, Total Therapy B. This regimen employs cycles of fractionated high‐dose cyclophosphamide, doxorubicin, and vincristine alternating with sequential infusions of high‐dose methotrexate and escalating doses of cytarabine, in addition to intensive intrathecal therapy. The planned duration of therapy is approximately 6 months. Two patients had B‐cell acute lymphoblastic leukemia and 26 had stage III B‐NHL; none had CNS involvement. The median age was 7 years. All 28 patients achieved complete remission (CR). Both patients with B‐ALL and 21 of 26 with stage III B‐NHL remain in CR, with a median follow‐up of 51 months. Treatment failures included 3 patients with recurrent or progressive disease, 1 toxic death in CR, and 1 patient who developed a secondary mediastinal T‐cell lymphoblastic lymphoma 4 1/2 years after the diagnosis of B‐NHL. The 2‐ and 5‐year event‐free survival rates were 85.7 ± 6.6{\%} (SE) and 79.6 ± 8.5{\%}, respectively. Total Therapy B is a highly effective therapy for children with advanced stage B‐NHL without CNS involvement. {\circledC} 1994 Wiley‐Liss, Inc.",
keywords = "Burkitt's lymphoma, leukemia, B‐cell, lymphoma, small noncleaved‐cell",
author = "Griffin, {Timothy C.} and Bowman, {W. Paul} and Winick, {Naomi J.} and Buchanan, {George R.}",
year = "1994",
doi = "10.1002/mpo.2950230502",
language = "English",
volume = "23",
pages = "393--399",
journal = "Medical and Pediatric Oncology",
issn = "0098-1532",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

Treatment of advanced stage diffuse, small non‐cleaved cell lymphoma in childhood : Further experience with total therapy B. / Griffin, Timothy C.; Bowman, W. Paul; Winick, Naomi J.; Buchanan, George R.

In: Medical and Pediatric Oncology, Vol. 23, No. 5, 1994, p. 393-399.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of advanced stage diffuse, small non‐cleaved cell lymphoma in childhood

T2 - Further experience with total therapy B

AU - Griffin, Timothy C.

AU - Bowman, W. Paul

AU - Winick, Naomi J.

AU - Buchanan, George R.

PY - 1994

Y1 - 1994

N2 - Prior to the development of intensive treatments for patients with advanced stage B‐cell non‐Hodgkin's lymphoma (B‐NHL), the prognosis for such patients was dismal. A minority of patients attained long‐term, disease‐free survival. Since 1981, we have treated 28 children with advanced stage B‐NHL with an intensive chemotherapeutic protocol, Total Therapy B. This regimen employs cycles of fractionated high‐dose cyclophosphamide, doxorubicin, and vincristine alternating with sequential infusions of high‐dose methotrexate and escalating doses of cytarabine, in addition to intensive intrathecal therapy. The planned duration of therapy is approximately 6 months. Two patients had B‐cell acute lymphoblastic leukemia and 26 had stage III B‐NHL; none had CNS involvement. The median age was 7 years. All 28 patients achieved complete remission (CR). Both patients with B‐ALL and 21 of 26 with stage III B‐NHL remain in CR, with a median follow‐up of 51 months. Treatment failures included 3 patients with recurrent or progressive disease, 1 toxic death in CR, and 1 patient who developed a secondary mediastinal T‐cell lymphoblastic lymphoma 4 1/2 years after the diagnosis of B‐NHL. The 2‐ and 5‐year event‐free survival rates were 85.7 ± 6.6% (SE) and 79.6 ± 8.5%, respectively. Total Therapy B is a highly effective therapy for children with advanced stage B‐NHL without CNS involvement. © 1994 Wiley‐Liss, Inc.

AB - Prior to the development of intensive treatments for patients with advanced stage B‐cell non‐Hodgkin's lymphoma (B‐NHL), the prognosis for such patients was dismal. A minority of patients attained long‐term, disease‐free survival. Since 1981, we have treated 28 children with advanced stage B‐NHL with an intensive chemotherapeutic protocol, Total Therapy B. This regimen employs cycles of fractionated high‐dose cyclophosphamide, doxorubicin, and vincristine alternating with sequential infusions of high‐dose methotrexate and escalating doses of cytarabine, in addition to intensive intrathecal therapy. The planned duration of therapy is approximately 6 months. Two patients had B‐cell acute lymphoblastic leukemia and 26 had stage III B‐NHL; none had CNS involvement. The median age was 7 years. All 28 patients achieved complete remission (CR). Both patients with B‐ALL and 21 of 26 with stage III B‐NHL remain in CR, with a median follow‐up of 51 months. Treatment failures included 3 patients with recurrent or progressive disease, 1 toxic death in CR, and 1 patient who developed a secondary mediastinal T‐cell lymphoblastic lymphoma 4 1/2 years after the diagnosis of B‐NHL. The 2‐ and 5‐year event‐free survival rates were 85.7 ± 6.6% (SE) and 79.6 ± 8.5%, respectively. Total Therapy B is a highly effective therapy for children with advanced stage B‐NHL without CNS involvement. © 1994 Wiley‐Liss, Inc.

KW - Burkitt's lymphoma

KW - leukemia, B‐cell

KW - lymphoma

KW - small noncleaved‐cell

UR - http://www.scopus.com/inward/record.url?scp=0028146199&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950230502

DO - 10.1002/mpo.2950230502

M3 - Article

C2 - 8084306

AN - SCOPUS:0028146199

VL - 23

SP - 393

EP - 399

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

SN - 0098-1532

IS - 5

ER -